Sign in

You're signed outSign in or to get full access.

PT

Perspective Therapeutics, Inc. (CATX)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 2024 results: revenue of $0.234M and GAAP EPS of -$0.243 missed S&P Global consensus ($0.277M revenue; -$0.242 EPS). The miss was driven largely by elevated operating expenses, including a non-cash goodwill impairment recorded in FY’24 that impacted quarterly normalized metrics.*
  • Full-year 2024 cash, cash equivalents and short-term investments were $227M, with runway extended into late 2026; management reiterated progress on clinical programs and manufacturing scale-up.
  • Clinical progress: VMT-α-NET showed durable disease control and emerging responses (1 confirmed, 2 unconfirmed PRs as of early 2025), with Cohort 2 reopened and 30 patients dosed by Feb 28, 2025; VMT01 initiated first-in-human combo dosing with nivolumab in March 2025.
  • Near-term catalysts: FDA alignment on Cohort 3 for VMT-α-NET, maturation of NET responses, VMT01 combo data readouts, and dosing initiation for PSV359 (FAP-α) mid-2025.

What Went Well and What Went Wrong

What Went Well

  • Demonstrated sustained disease control and early tumor responses in VMT-α-NET: “1 objective response and 8/9 patients with durable disease control” in early cohorts; subsequent updates showed deepening responses with delayed radiobiologic effects.
  • Manufacturing scale-up: second Somerset, NJ facility commenced shipping 212Pb-labeled product in Q4 2024; three additional buildings acquired (Houston, Chicago, Los Angeles) to build distributed finishing capacity.
  • Strong cash position and extended runway: “Cash, cash equivalents and short-term investments… approximately $227M… sufficient to fund… into late 2026.”
  • CEO tone on execution: “On track for multiple clinical updates through mid-2026… expanding manufacturing capabilities… expected to be sufficient to fund… into late 2026.”

What Went Wrong

  • Miss vs Street in Q4: revenue and EPS slightly below consensus; normalized net income significantly below consensus, primarily due to FY’24 goodwill impairment that flowed through year-end. *
  • Operating expense ramp: FY’24 R&D up ~95% YoY to $41.6M and G&A up ~26% YoY to $26.6M as the company scaled clinical and manufacturing operations.
  • Regulatory timing uncertainty: progression to Cohort 3 in VMT-α-NET requires FDA alignment; management refrained from commenting on active discussions, indicating gating of dose escalation timing.

Financial Results

MetricQ2 2024Q3 2024Q4 2024
Revenue ($USD Millions)$0.526 $0.369 $0.234*
GAAP EPS ($)-$0.18 -$0.21 -$0.243*
EBITDA ($USD Millions)-$13.691*-$17.965*-$20.193*
Net Loss / Normalized ($USD Millions)-$11.704 -$15.122 -$40.169*

Values marked with * retrieved from S&P Global.

Revenue and EPS vs S&P Global consensus – Q4 2024:

MetricConsensusActualSurprise
Revenue ($USD Millions)$0.277*$0.234*-$0.043*
GAAP EPS ($)-$0.242*-$0.243*-$0.002*
Net Income Normalized ($USD Millions)-$18.056*-$40.169*-$22.113*

Segment/KPI highlights:

MetricQ2 2024Q3 2024Q4 2024
Grant Revenue ($USD Millions)$0.526 $0.369 $0.234*
VMT-α-NET Cohort 2 patients dosed (cumulative)7 (DLT completed) 18 (through YE 2024) 30 (as of Feb 28, 2025)

Values marked with * retrieved from S&P Global.

YoY comparison – Q4:

MetricQ4 2023Q4 2024YoY Change
Revenue ($USD Millions)$0.337*$0.234*-30.6%*
EBITDA ($USD Millions)-$11.457*-$20.193*-$8.736*
Net Income Normalized ($USD Millions)-$24.675*-$40.169*-$15.494*

Values marked with * retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayMulti-year“Into mid-2026” (Q3 2024) “Into late 2026” (FY 2024) Raised runway
VMT01 (MC1R)2025Combo cohort open for enrollment with nivolumab First patient dosed in combo cohort (Mar 2025); monotherapy at 1.5 mCi open Progressed to dosing
PSV359 (FAP-α)Mid-2025IND filing targeted late 2024 IND cleared; “study may proceed” with dosing expected mid-2025 Initiation confirmed
Manufacturing2024-2025Somerset facility “started shipping” (Q4 2024) Somerset shipping; 3 new sites acquired; €49M equipment/services commitment with Comecer Capacity expansion underway

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 & Q3 2024)Current Period (Q4 2024)Trend
FDA alignment (VMT-α-NET)SMC recommended dose escalation; Cohort 3 pending FDA consultation Ongoing FDA interactions; will disclose upon alignment; Cohort 2 reopened and expanded Progressing; cautious disclosure
VMT-α-NET efficacy & safetyEarly cohorts: no DLTs; durable disease control observed Deepening responses; 1 confirmed PR, 2 unconfirmed PRs; delayed radiobiologic effects clarified Improving clinical signal
VMT01 dosing strategy3 mCi showed stability; 5 mCi less favorable; plan to explore lower dose 1.5 mCi monotherapy and combo with nivolumab initiated (Mar 2025) Pivot to combo at lower dose
Manufacturing & supply chainSomerset facility operational; DOE thorium supply Expanded network; DOE supply sufficient; on-demand regional finishing Scaling capacity
Macro/tariffs/NIHNot highlightedTariffs not a factor (DOE sourcing); NIH cuts impacting trial sites’ operations External headwinds noted
FAP-α program (PSV359)IND planned; preclinical/human imaging promising IND cleared; dosing expected mid-2025 Advancing to clinic

Management Commentary

  • “On track for multiple clinical updates through mid-2026… building out recently acquired sites… Cash… approximately $227M… sufficient… into late 2026.” — CEO Thijs Spoor, FY’24 press release
  • “2025 is just the beginning… transformation into a clinical-stage company… patient-first approach…” — CEO ahead of J.P. Morgan
  • On VMT-α-NET data maturation: “Delayed response after treatment… radiation can work later in these tumors… encouraging vs beta emitter in low-proliferation tumors.” — Prof. Richard Wahl (ASCO-GI call)
  • On manufacturing: “Somerset, NJ… commercial-ready… shipping by ground across the East Coast and by air across the U.S.” — CEO conference remarks

Q&A Highlights

  • FDA path and dosing: Management will update once Cohort 3 alignment is finalized; fixed-dose approach collects broad data before deciding on weight-based dosing.
  • Safety/dosimetry: Kidney dose concerns at higher VMT01 doses were calculated, not clinically observed; strategy is dose reduction to lower exposure.
  • Macro risks: NIH funding cuts are acutely impacting clinical sites’ operating budgets and patient care; tariffs not a factor due to DOE sourcing.
  • Clinical strategy: For VMT01, lower-dose monotherapy showed disease stability; combination with PD-1 inhibitor (nivolumab) initiated to harness immunostimulatory synergy.

Estimates Context

  • Q4 2024 vs S&P Global consensus: revenue $0.234M vs $0.277M (miss); EPS -$0.243 vs -$0.242 (slight miss); normalized net income -$40.169M vs -$18.056M (miss), largely impacted by the non-cash goodwill impairment recorded in FY’24. *
  • Prior quarters: Q3 2024 revenue $0.369M actual vs $0.238M consensus (beat); EPS -$0.21 actual vs -$0.192 consensus (miss). *
  • Implication: Street models likely need to reflect higher opex levels tied to clinical enrollment and manufacturing build-out, plus non-recurring FY’24 impairment effects.*

Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • Q4 misses were modest on revenue/EPS; the outsized normalized loss reflects FY’24 goodwill impairment rather than worsening core operations.
  • Clinical momentum is tangible: VMT-α-NET shows durable control and deepening responses; watch FDA alignment for Cohort 3 and 2H’25 congress submissions.
  • VMT01 strategic pivot to lower-dose and PD-1 combo is underway; early monotherapy stability supports this direction, with first combo dosing in March 2025.
  • Manufacturing capacity and isotope supply-chain de-risked: Somerset shipping, new facilities building out, DOE thorium supply sufficient for 2025 clinical needs.
  • Cash runway into late 2026 provides ample time to mature data across three clinical programs and scale finishing network; dilution risk moderated near term.
  • Near-term trading setup: data cadence (ASCO-GI follow-ups, conference updates), FDA cohort decisions, and combo initiation updates are likely stock movers; macro NIH cuts could affect site throughput.
  • Medium-term thesis: differentiated 212Pb platform with theranostic pairing (203Pb/212Pb), proprietary chelator, and distributed manufacturing positions CATX to potentially improve efficacy/safety vs beta emitters in select tumors.

Source documents read in full:

  • Form 8-K (Item 2.02) and Exhibit 99.1 press release for Q4/FY 2024 (Mar 26, 2025)
  • Business update 8-K (Jan 13, 2025) and exhibits
  • Q3 2024 press release and financials (Nov 12, 2024)
  • Q2 2024 press release and financials (Aug 12, 2024)
  • Investor/analyst transcripts (Jan–Mar 2025): ASCO-GI investor call, Oppenheimer conference, Barclays Q&A – – –

Values marked with * retrieved from S&P Global.